API

Aop: 36

AOP Title

?


Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis

Short name:

?

Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis

Authors

?


Michelle Angrish, Brian Chorley, U.S. EPA

Point of Contact

?


Michelle Angrish

Contributors

?


  • Brian Chorley
  • Michelle Angrish
  • Lyle Burgoon

Status

?

Author status OECD status OECD project SAAOP status
Under development: Not open for comment. Do not cite Under Development 1.29 Included in OECD Work Plan


This AOP was last modified on February 26, 2017 20:08

?

Revision dates for related pages

Page Revision Date/Time
Decreased, PPAR-alpha activation September 16, 2017 10:14
Decreased, PPAR-beta activation September 16, 2017 10:14
Decreased, PPAR-gamma activation September 16, 2017 10:14
Accumulation, Fatty acid September 16, 2017 10:14
Decreased, HSD17B10 expression September 16, 2017 10:14
Decreased, Mitochondrial fatty acid beta-oxidation September 16, 2017 10:14
Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity September 16, 2017 10:14
Increased, Liver Steatosis September 16, 2017 10:14
Decreased, PPAR-alpha activation leads to Decreased, HSD17B10 expression December 03, 2016 16:37
Decreased, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid December 03, 2016 16:37
Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity leads to Decreased, Mitochondrial fatty acid beta-oxidation December 03, 2016 16:37
Decreased, HSD17B10 expression leads to Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity December 03, 2016 16:37
Decreased, PPAR-beta activation leads to Decreased, HSD17B10 expression December 03, 2016 16:37
Decreased, PPAR-gamma activation leads to Decreased, HSD17B10 expression December 03, 2016 16:37
Accumulation, Fatty acid leads to Increased, Liver Steatosis December 03, 2016 16:37

Abstract

?



Background (optional)

?



Summary of the AOP

?



Stressors

?


Molecular Initiating Event

?

Title Short name
Decreased, PPAR-alpha activation Decreased, PPAR-alpha activation
Decreased, PPAR-beta activation Decreased, PPAR-beta activation
Decreased, PPAR-gamma activation Decreased, PPAR-gamma activation

Key Events

?

Title Short name
Accumulation, Fatty acid Accumulation, Fatty acid
Decreased, HSD17B10 expression Decreased, HSD17B10 expression
Decreased, Mitochondrial fatty acid beta-oxidation Decreased, Mitochondrial fatty acid beta-oxidation
Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity

Adverse Outcome

?

Title Short name
Increased, Liver Steatosis Increased, Liver Steatosis

Relationships Between Two Key Events (Including MIEs and AOs)

?

Network View

?

 

Life Stage Applicability

?


Taxonomic Applicability

?


Sex Applicability

?


Graphical Representation

?

Click to download graphical representation template

Overall Assessment of the AOP

?



Consider the following criteria (may include references to KE Relationship pages): 1. concordance of dose-response relationships; 2. temporal concordance among the key events and adverse effect; 3. strength, consistency, and specificity of association of adverse effect and initiating event; 4. biological plausibility, coherence, and consistency of the experimental evidence; 5. alternative mechanisms that logically present themselves and the extent to which they may distract from the postulated AOP. It should be noted that alternative mechanisms of action, if supported, require a separate AOP; 6. uncertainties, inconsistencies and data gaps.

Domain of Applicability

?


Essentiality of the Key Events

?


Weight of Evidence Summary

?


Quantitative Considerations

?


Considerations for Potential Applications of the AOP (optional)

?



References

?